| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Hiroshi Handa | |
| Takumi Ito | |||
| Hideki Ando | |||
| P2860 | cites work | The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage | Q24301297 |
| Identification of a primary target of thalidomide teratogenicity | Q24302178 | ||
| Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery | Q24302241 | ||
| CSA-dependent degradation of CSB by the ubiquitin-proteasome pathway establishes a link between complementation factors of the Cockayne syndrome | Q24338620 | ||
| PTEN function: how normal cells control it and tumour cells lose it | Q24528114 | ||
| A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation | Q24532087 | ||
| Thalidomide is an inhibitor of angiogenesis | Q24563363 | ||
| A gene atlas of the mouse and human protein-encoding transcriptomes | Q24568043 | ||
| Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation | Q24653215 | ||
| Thalidomide analogues as anticancer drugs | Q24670383 | ||
| Stages of embryonic development of the zebrafish | Q27860947 | ||
| Function and regulation of cullin-RING ubiquitin ligases | Q28131707 | ||
| Back to the future with ubiquitin | Q28240711 | ||
| The mesenchymal factor, FGF10, initiates and maintains the outgrowth of the chick limb bud through interaction with FGF8, an apical ectodermal factor | Q28241059 | ||
| Thalidomide inhibits the replication of human immunodeficiency virus type 1 | Q28378516 | ||
| Identification and functional characterization of cereblon as a binding protein for large-conductance calcium-activated potassium channel in rat brain | Q28572874 | ||
| Cereblon is expressed in the retina and binds to voltage-gated chloride channels | Q28583805 | ||
| Effective targeted gene 'knockdown' in zebrafish | Q29547445 | ||
| Animal models of human disease: zebrafish swim into view | Q29615723 | ||
| Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals | Q30830907 | ||
| Thalidomide-induced limb defects: resolving a 50-year-old puzzle | Q33348200 | ||
| Efficacy of lenalidomide in myelodysplastic syndromes | Q33364909 | ||
| Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study | Q33373186 | ||
| Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential uses | Q33753486 | ||
| Hypothesis: thalidomide embryopathy-proposed mechanism of action | Q33831075 | ||
| Antitumor activity of thalidomide in refractory multiple myeloma | Q33880642 | ||
| Mechanism of action in thalidomide teratogenesis | Q33900903 | ||
| Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia | Q34021937 | ||
| Formation of the digestive system in zebrafish. II. Pancreas morphogenesis. | Q34225514 | ||
| Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients | Q34346713 | ||
| UV-induced ubiquitylation of XPC protein mediated by UV-DDB-ubiquitin ligase complex. | Q34417183 | ||
| Thalidomide, a current teratogen in South America | Q34421312 | ||
| Thalidomide metabolism by the CYP2C subfamily. | Q34523961 | ||
| DCAFs, the missing link of the CUL4-DDB1 ubiquitin ligase | Q34641190 | ||
| Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man. | Q34646752 | ||
| Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia | Q35033514 | ||
| The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways | Q35103813 | ||
| DDB complexities | Q35216371 | ||
| Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes | Q36229974 | ||
| Molecular mechanism of nrf2 activation by oxidative stress | Q36342665 | ||
| Thalidomide induces limb anomalies by PTEN stabilization, Akt suppression, and stimulation of caspase-dependent cell death | Q36421389 | ||
| The thalidomide saga | Q36763353 | ||
| Lenalidomide for the treatment of B-cell malignancies | Q37088809 | ||
| Shedding light on an old mystery: thalidomide suppresses survival pathways to induce limb defects | Q37140396 | ||
| Development and application of high-performance affinity beads: toward chemical biology and drug discovery | Q37401236 | ||
| High-performance affinity beads for identifying drug receptors | Q38309653 | ||
| Fgf8 is required for outgrowth and patterning of the limbs | Q38525644 | ||
| Thalidomide for the therapy of graft-versus-host disease following allogeneic bone marrow transplantation | Q38769333 | ||
| Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity | Q39225712 | ||
| A short history of thalidomide embryopathy | Q39562228 | ||
| Proposed mechanisms of action in thalidomide embryopathy | Q39562235 | ||
| The Wnt antagonist Dickkopf-1 is regulated by Bmp signaling and c-Jun and modulates programmed cell death | Q39646720 | ||
| Induction of cereblon by NF-E2-related factor 2 in neuroblastoma cells exposed to hypoxia-reoxygenation | Q39670241 | ||
| Thalidomide embryopathy | Q39678672 | ||
| Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathway | Q40174117 | ||
| Malignant reversion of a human osteosarcoma cell line, Saos-2, by inhibition of NFkappaB. | Q40703484 | ||
| S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide | Q40816692 | ||
| Biochemical toxicology of chemical teratogenesis | Q41068123 | ||
| Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide | Q41937062 | ||
| Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization | Q42547622 | ||
| Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases | Q42800101 | ||
| Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation | Q42941758 | ||
| Misregulation of gene expression in the redox-sensitive NF-kappab-dependent limb outgrowth pathway by thalidomide | Q44146012 | ||
| Thalidomide metabolites in mice and patients with multiple myeloma | Q44435171 | ||
| Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues | Q44480741 | ||
| A novel hypothesis for thalidomide-induced limb teratogenesis: redox misregulation of the NF-kappaB pathway | Q44720745 | ||
| Use of the rat postimplantation embryo culture to assess the embryotoxic potency within a chemical category and to identify toxic metabolites | Q44742372 | ||
| The evolution of thalidomide and its IMiD derivatives as anticancer agents | Q44824886 | ||
| Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate | Q45291431 | ||
| Fgf8 signalling from the AER is essential for normal limb development. | Q45967231 | ||
| Thalidomide resistance is based on the capacity of the glutathione-dependent antioxidant defense. | Q46015387 | ||
| Development of novel magnetic nano-carriers for high-performance affinity purification | Q46722982 | ||
| An autopodial-like pattern of Hox expression in the fins of a basal actinopterygian fish. | Q47784218 | ||
| Thalidomide a promising new treatment for rheumatoid arthritis | Q49067573 | ||
| A new mechanism of methotrexate action revealed by target screening with affinity beads. | Q51140231 | ||
| BMP signals control limb bud interdigital programmed cell death by regulating FGF signaling. | Q51984534 | ||
| The limb bud Shh-Fgf feedback loop is terminated by expansion of former ZPA cells. | Q52088637 | ||
| Fin development in a cartilaginous fish and the origin of vertebrate limbs. | Q52121697 | ||
| BMPs negatively regulate structure and function of the limb apical ectodermal ridge. | Q52180021 | ||
| Free radical intermediates of phenytoin and related teratogens. Prostaglandin H synthase-catalyzed bioactivation, electron paramagnetic resonance spectrometry, and photochemical product analysis. | Q53946261 | ||
| Thalidomide | Q56091164 | ||
| New cases of thalidomide embryopathy in Brazil | Q56786143 | ||
| The development of the paired fins in the Zebrafish (Danio rerio) | Q60307652 | ||
| Imperforate anus in 700,000 consecutive liveborn infants | Q67233778 | ||
| Thalidomide for the treatment of chronic graft-versus-host disease | Q68075890 | ||
| Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers | Q69374372 | ||
| Treatment of Behçet's disease with thalidomide | Q69661070 | ||
| Teratogen metabolism: thalidomide activation is mediated by cytochrome P-450 | Q70008472 | ||
| DRUG TESTING IN ANIMALS FOR TERATOGENIC EFFECTS. THALIDOMIDE IN THE PREGNANT RAT | Q76818958 | ||
| Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent | Q77134015 | ||
| THALIDOMIDE IN THE TREATMENT OF LEPRA REACTIONS | Q78373559 | ||
| TERATOGENIC EFFECTS OF THALIDOMIDE IN RABBITS, RATS, HAMSTERS, AND MICE | Q78381187 | ||
| The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies | Q79447470 | ||
| P433 | issue | 9 | |
| P921 | main subject | thalidomide | Q203174 |
| teratogenicity | Q56246640 | ||
| P304 | page(s) | 1569-1579 | |
| P577 | publication date | 2011-01-05 | |
| P1433 | published in | Cellular and Molecular Life Sciences | Q5058352 |
| P1476 | title | Teratogenic effects of thalidomide: molecular mechanisms | |
| P478 | volume | 68 |
| Q96431668 | A comprehensive map of disease networks and molecular drug discoveries for glaucoma |
| Q28543087 | A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts |
| Q47220547 | Attenuation of nephritis in lupus-prone mice by thalidomide. |
| Q39511261 | Back to the future: revisiting HIV-1 lethal mutagenesis |
| Q53687540 | Baicalein Inhibits Proliferation of Myeloma U266 Cells by Downregulating IKZF1 and IKZF3. |
| Q64064089 | Cereblon Control of Zebrafish Brain Size by Regulation of Neural Stem Cell Proliferation |
| Q38909210 | Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs. |
| Q46054966 | Cereblon: A Protein Crucial to the Multiple Functions of Immunomodulatory Drugs as well as Cell Metabolism and Disease Generation. |
| Q87766362 | Chiral ligand-exchange resolution of underivatized amino acids on a dynamically modified stationary phase for RP-HPTLC |
| Q55295737 | Distribution of pomalidomide into semen of healthy male subjects after multiple doses. |
| Q92149062 | Drug ReposER: a web server for predicting similar amino acid arrangements to known drug binding interfaces for potential drug repositioning |
| Q26744021 | Drug safety: The concept, inception and its importance in patients' health |
| Q38698182 | Embryonic stem cells and the next generation of developmental toxicity testing. |
| Q38186030 | Evaluation of Signaling Pathways Involved in γ-Globin Gene Induction Using Fetal Hemoglobin Inducer Drugs |
| Q33846806 | Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma. |
| Q38954066 | Gene-environment interactions in development and disease |
| Q34406463 | Identification of thalidomide-specific transcriptomics and proteomics signatures during differentiation of human embryonic stem cells |
| Q87149157 | Immune modulatory effect of thalidomide on T cells |
| Q37104408 | In silico analysis of enantioselective binding of immunomodulatory imide drugs to cereblon |
| Q53009751 | Inhibition of Uterine Contractility by Thalidomide Analogs via Phosphodiesterase-4 Inhibition and Calcium Entry Blockade. |
| Q35171777 | Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma |
| Q54261892 | Myeloid disease: Another action of a thalidomide derivative. |
| Q34373253 | Novel insights into the mechanism of action of lenalidomide |
| Q55309345 | Polymorphisms in the promoter region of the CRBN gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients. |
| Q41545464 | Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy |
| Q38987429 | Prenatal exposure to environmental factors and congenital limb defects |
| Q40113622 | Prescription drug use during pregnancy in France: a study from the national health insurance permanent sample |
| Q46304317 | Redox stress and signaling during vertebrate embryonic development: Regulation and responses. |
| Q91322597 | SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate |
| Q38267996 | SCF ubiquitin ligase-targeted therapies. |
| Q46520980 | Separation mechanism of chiral impurities, ephedrine and pseudoephedrine, found in amphetamine-type substances using achiral modifiers in the gas phase |
| Q48191012 | Structural basis of thalidomide enantiomer binding to cereblon |
| Q54627325 | Systems biology-embedded target validation: improving efficacy in drug discovery. |
| Q57129133 | Thalidomide Embryopathy: An Enigmatic Challenge |
| Q96647339 | Thalidomide-Revisited: Are COVID-19 Patients Going to Be the Latest Victims of Yet Another Theoretical Drug-Repurposing? |
| Q38074017 | Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. |
| Q28085087 | Thalidomide-induced teratogenesis: history and mechanisms |
| Q38415594 | The fish embryo test (FET): origin, applications, and future |
| Q26783814 | The role and mechanism of CRL4 E3 ubiquitin ligase in cancer and its potential therapy implications |
| Q38121762 | Therapeutic effects of thalidomide in hematologic disorders: a review |
| Q50686302 | Toxicity assessment of 7 anticancer compounds in zebrafish. |
| Q37679962 | Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature. |
| Q59328998 | Understanding the Thalidomide Chirality in Biological Processes by the Self-disproportionation of Enantiomers |
| Q42675692 | Vascular endothelial growth receptor 1 acts as a stress-associated protein in the therapeutic response to thalidomide |
| Q24635072 | What is the functional role of the thalidomide binding protein cereblon? |
Search more.